Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic CancerGlobe Newswire • 10 days ago
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell...
Share to Feed
DekaBank Deutsche Girozentrale boosted its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 43.1% during the fourth quarter, according to the company in its most recent filing with the...
Fifth Third Bancorp boosted its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 3,881.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC...
BioNTech SE (NASDAQ:BNTX Get Free Report) has been assigned a consensus rating of Hold from the ten ratings firms that are covering the stock, MarketBeat.com reports. One...
WuXi Biologics Reports Solid 2023 Annual Results WuXi Biologics Reports Solid 2023 Annual Results PR Newswire HONG KONG, March 26, 2024 Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross...
Shares of BioNTech SE (NASDAQ:BNTX Get Free Report) have earned an average rating of Hold from the twelve ratings firms that are currently covering the company, Marketbeat...
This indicator may be signaling that BNTX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and ten...
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management...